Janux Therapeutics Inc Cash Flow-to-Debt Ratio
Janux Therapeutics Inc cash flow-to-debt ratio. Janux Therapeutics Inc (JANX) has a Cash Flow-to-Debt Ratio of -0.14x as of March 2026, meaning its operating cash flow of $-12.34 Million could theoretically repay 0% of its total liabilities ($86.69 Million) in one year. See JANX financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Janux Therapeutics Inc (2019–2025)
Cash flow-to-debt ratio of Janux Therapeutics Inc from 2019 to 2025. Historical debt coverage capacity for Janux Therapeutics Inc across 7 annual periods. Check JANX total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Janux Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
Janux Therapeutics Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Janux Therapeutics Inc. For the full cash flow conversion analysis, see cash flow conversion of Janux Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.62x | $-82.23 Million | $50.70 Million | ▼ -43.4% |
| 2024 | -1.13x | $-43.81 Million | $38.73 Million | ▲ +19.4% |
| 2023 | -1.40x | $-50.58 Million | $36.06 Million | ▼ -41.4% |
| 2022 | -0.99x | $-42.92 Million | $43.27 Million | ▲ +21.1% |
| 2021 | -1.26x | $-16.98 Million | $13.50 Million | ▼ -788.3% |
| 2020 | -0.14x | $-4.37 Million | $30.86 Million | ▲ +68.1% |
| 2019 | -0.44x | $-3.83 Million | $8.62 Million | — |